Filtered By:
Specialty: Neurology
Cancer: Acute Leukemia

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 19 results found since Jan 2013.

Role of beta‐defensin 2 and interleukin‐4 receptor as stroke outcome biomarkers
Abstract Acute ischemic stroke is a complex disease with huge interindividual evolution variability that makes challenging the prediction of an adverse outcome. Our aim was to study the association of bloodstream signatures to early neurological outcome after stroke, by combining a subpooling of samples strategy with protein array discovery approach. Plasma samples from 36 acute stroke patients (< 4.5 h from onset) were equally pooled within outcome groups: worsening, stability, and improvement (n = 3 pools of four patients each, for each outcome group). These nine pools were screened using a 177 antibodies library,...
Source: Journal of Neurochemistry - February 11, 2014 Category: Neurology Authors: Teresa García‐Berrocoso, Dolors Giralt, Alejandro Bustamante, Victor Llombart, Marta Rubiera, Anna Penalba, Cristina Boada, Marc Espadaler, Carlos Molina, Joan Montaner Tags: Original Article Source Type: research

Stroke like syndrome and simple partial seizures secondary to intrathecal methotrexate use for the treatment of acute lymphocytic leukemia. (p6.181)
Conclusions:Our case may be the first reported of seizures and stroke like syndrome in the same patient for ALL treated with MTX. Clinicians should include Methotrexate induced leukoencephalopathy in their differential of seizures, stroke like syndrome and a combination of both. MRI DWI, ADC and FLAIR images should be included in the diagnostic evaluation of MTX induced encephalopathy especially with IT methotrexate.Disclosure: Dr. Fares has nothing to disclose. Dr. Silliman has received research support from Sanofi Genzyme, Biogen Idec, Bristol Myers and Novartis.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Fares, M.-A., Silliman, S. Tags: Neurologic Complications of Cancer Source Type: research

Methotrexate Neurotoxicity Mimicking Stroke (P2.296)
Conclusion: It is important for clinicians to recognize methotrexate-induced neurotoxcity as a possible stroke mimic.Disclosure: Dr. Pham has nothing to disclose. Dr. Ermak has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Pham, Q., Ermak, D. Tags: Cerebrovascular Disease and Interventional Neurology: Inflammation and Immunology Source Type: research

Methotrexate induced leucoencephalopathy: A stroke mimic
We describe the case of a 17 year old girl with acute lymphoblastic leukemia, who developed stroke like episodes on two consecutive challenges with a chemotherapeutic regime which included intravenous and intrathecal methotrexate. She had MRI changes consistent with acute ischemic stroke on both occasions. Her deficits recovered completely and spontaneously, as did the MRI changes. She did not have any further episodes when methotrexate was excluded from the chemotherapeutic regime.
Source: Annals of Indian Academy of Neurology - August 26, 2013 Category: Neurology Authors: Tushar D GosaviMohammed Tauqeer AhmadLai-Heng LeeShih-Hui Lim Source Type: research

Thiamine Deficiency While on Total Parenteral Nutrition Mimicking Acute Stroke: A Case Report (P3.217)
CONCLUSIONS: Thiamine deficiency mimicking stroke while on total parenteral nutrition has been rarely documented. Recognition of this syndrome is critical as prompt treatment may reverse symptoms.Disclosure: Dr. Parker has nothing to disclose. Dr. Marafie has nothing to disclose. Dr. Wolf has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Parker, A., Marafie, D., Wolf, V. Tags: Neurocritical Care: Clinical Science and Therapeutics Source Type: research

A Unique Presentation of Pediatric Stroke Attributed to Intrathecal Methotrexate (P3.309)
CONCLUSIONS:This is a rare case of ischemic watershed infarcts with diffuse reversible cerebral vasospasm, after intrathecal methotrexate. This highlights the need for further research into the pathogenesis of methotrexate neurotoxicity including endothelial damage.Study Supported by:Disclosure: Dr. Ilyas has nothing to disclose. Dr. Williams has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Ilyas, M., Williams, M. Tags: Neurologic Complications of Cancer Source Type: research

Progressive thrombosis of cervical and intracranial arteries related to Ponatinib treatment for Chronic Myeloid Leukemia
Ponatinib is a third-generation Tyrosine Kinase Inhibitor (TKI), approved as first-line treatment for Chronic Myeloid Leukaemia (CML) chronic phase.Here we describe a CML patient with a history of subsequent TIAs and an ischemic stroke during Ponatinib treatment. Patient was admitted for a 3-day history of sudden onset left hemiparesis due to an acute ischemic stroke. MRI showed bilaterally the almost total absence of signal in the intracranial tract of anterior circulation and low signal of cerebral posterior circulation.
Source: Journal of Stroke and Cerebrovascular Diseases - August 15, 2020 Category: Neurology Authors: E Spina, R Renna, LA Lanterna, ML Colleoni, V Andreone Tags: Case Report Source Type: research

Neuregulin-1/PI3K signaling effects on oligodendrocyte proliferation, remyelination and behaviors deficit in a male mouse model of ischemic stroke
In this study, we investigated the effect of neuregulin-1 (NRG1) on demyelination and neurological function in an ischemic stroke model, and further explored its neuroprotective mechanisms. Adult male ICR mice underwent photothrombotic ischemia surgery and were injected with NRG1 beginning 30 min after ischemia. Cylinder and grid walking tests were performed to evaluate the forepaw function. In addition, the effect of NRG1 on neuronal damage/death (Cresyl violet, CV), neuronal nuclei (NeuN), nestin, doublecortin (DCX), myelin basic protein (MBP), non-phosphorylated neurofilaments (SMI-32), adenomatous polyposis coli (APC),...
Source: Experimental Neurology - January 23, 2023 Category: Neurology Authors: Mai Yin Cui Yan Qiong Fu Zhuo Li Li Yu Zheng Yi Yu Chan Zhang Yun Qi Zhang Bing Rui Gao Wu Yue Chen Yun-Lyul Lee Moo-Ho Won Min Liao Yong Jian Bai Hui Chen Source Type: research

A Not Uncommon Cause of Stroke Mimicker in Children
A 16 year old young man with history of acute lymphoblastic leukemia presented with acute onset of right hemibody and facial numbness, which progressed to right sided weakness(arm>leg), right facial droop, and aphasia. A stroke alert code was activated and brain magnetic resonance imaging (MRI) revealed focal areas of restricted diffusion in the centrum semiovale bilaterally, slightly more extensively on the left than the right (figure 1). MR angiogram of the head and neck was unremarkable.
Source: Pediatric Neurology - November 13, 2017 Category: Neurology Authors: Erin Willis, Debopam Samanta, Alisa Kanfi Tags: Visual Diagnosis Source Type: research

Nilotinib-Associated Atherosclerosis Presenting as Multifocal Intracranial Stenosis and Acute Stroke
Nilotinib is considered an effective and well-tolerated frontline agent used in the treatment of chronic myelogenous leukemia (CML). It is a breakpoint cluster region-Ableson (BCR-ABL) tyrosine kinase inhibitor (TKI) that has been associated with accelerated arterial stenosis, presumably of atherosclerotic etiology. However, reports are mostly limited to peripheral artery occlusive disease (PAOD), specifically in the lower extremities.1 The mechanism by which it promotes atherosclerosis is poorly understood but endothelial and perivascular factors, mast cell depletion, and metabolic factors such as promotion of dyslipidemi...
Source: Journal of Stroke and Cerebrovascular Diseases - June 2, 2021 Category: Neurology Authors: Bhavika Kakadia, Richa Thakkar, Emma Sanborn, Giselle Alexandra Suero-Abreu, Tudor G. Jovin, Ryna Then Tags: Case Report Source Type: research

Cerebrovascular manifestations in hematological diseases: an update
AbstractPatients with hematological diseases often experience cerebrovascular complications including ischemic stroke, intracerebral and subarachnoid hemorrhage, microbleeds, posterior reversible encephalopathy syndrome, and dural sinus and cerebral vein thrombosis (CVT). In this update, we will review recent advances in the management of cerebrovascular diseases in the context of myeloproliferative neoplasms, leukemias, lymphomas, multiple myeloma, POEMS, paroxysmal nocturnal hemoglobinuria (PNH), thrombotic thrombocytopenic purpura (TTP), and sickle-cell disease. In acute ischemic stroke associated with hematological dis...
Source: Journal of Neurology - February 13, 2021 Category: Neurology Source Type: research

Challenging Cases in Cerebrovascular Disease
We present four cases of stroke of uncommon cause and remind clinicians to be open minded to the many possible causes of stroke, in particular because early recognition and treatment is often critical. Case 1 discusses a patient with inflammatory cerebral amyloid angiopathy. The presentation, ability to recur, and current treatment considerations are reviewed. Case 2 discusses microangiopathic thrombotic angiopathy. Diagnosis and treatment are considered. An association with interferon therapy and the evolving terminology of this and related conditions are discussed. Case 3 discusses intracranial hemorrhage secondary to ac...
Source: Seminars in Neurology - January 9, 2023 Category: Neurology Authors: Kelly, Michael A. Singh, Jasmine Balabanov, Alexandra Wadina, Adam Dasovic, Braden Tags: Review Article Source Type: research

Methotrexate Encephalopathy as a Cause of Alternating Hemiplegia (P3.143)
CONCLUSIONS: Transient neurologic dysfunction with reversible MRI abnormality is a recognized consequence of intrathecal methotrexate chemotherapy in childhood ALL. Patients present with dramatic fluctuating neurologic symptoms with associated MRI changes and may be mistaken for stroke or a seizure disorder. Once the syndrome is recognized patients typically recover with supportive management and rehabilitation.Disclosure: Dr. Sullivan has nothing to disclose. Dr. Quealy has nothing to disclose. Dr. Olsevskaite has nothing to disclose. Dr. MacEneaney has nothing to disclose. Dr. Ryan has nothing to disclose. Dr. O'Toole ha...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Sullivan, C., Quealy, J., Olsevskaite, J., MacEneaney, P., Ryan, C., O'Toole, O. Tags: Neuro-oncology: CNS Lymphoma and Other Hematologic Malignancies Source Type: research